PainChek® expands presence in New Zealand through partnership with Medi-map Medication Management

HIGHLIGHTS

- Opens an opportunity for PCK to rapidly expand into the New Zealand residential aged care market
- Medi-map to provide lead generation and marketing support to PainChek
- Medi-map have approximately 80% of the New Zealand residential aged care market under contract
- Sales and implementation to commence immediately
- Data flow available between both best in breed pain assessment and medication management systems allows for real time pain medication management

PainChek® Ltd (ASX: PCK) ("PainChek®" or "the Company"), developer of the world's first smart phone-based pain assessment and monitoring application, is pleased to announce an international partnership program with leading New Zealand medication management system, Medi-map.

The Medi-map platform is the leading medication management software for aged care providers in New Zealand. The platform manages all aspects of medication in a facility-based environment sharing the medication charts between prescriber, pharmacy and care organization staff allowing for a transparent, seamless cascade of care for each resident.

Medi-map and PainChek will collaborate through Medi-map's promotion of PainChek to their New Zealand Aged Care clients and the integration of PainChek results into the Medi-map platform to further enhance the seamless delivery of care. PainChek remains responsible for direct sales, implementation, training and technical support to the New Zealand client base.

CEO of Medi-map Greg Garratt said:

"We are thrilled to Partner with PainChek in the New Zealand market. There are such great working synergies between both companies. Combining best in breed pain assessment with real time medication management is extremely exciting and powerful from a resident outcome's perspective. Integrating PainChek results into Medi-map will lead to improved resident outcomes and better care. Something both companies are passionate about"

The New Zealand market presents another sizeable market opportunity for PainChek, where there are almost 40,000 residents in aged care and 70,000 people living with Dementia[1]. PainChek currently has Enliven as a customer in NZ with 300 beds under contract.

PainChek® CEO Philip Daffas said:

"We have built a strong working relationship with Medi-map for some time and share the same goals in terms of delivering better care within aged care. Integrating PainChek pain assessments with the Medi-map medication system provides carers with the ability to diagnose and treat residents in pain in real time. This is a great step forward. The collaboration is another example of our digital capability, delivering PainChek to international clients in a cost-effective, integrated way and through a flexible business model built for modern day healthcare."

1 https://www.alzheimers.org.nz/our-voice/new-zealand-data

ABN 21 146 035 127   **P:** +61 8 9388 8290
401, 35 Lime Street,   **E:** info@painchek.com
Sydney, NSW, 2000   **W:** painchek.com

PainChek Limited (ASX: PCK) | PG 1

Active selling to New Zealand clients commences from 1st November 2020. PainChek and Medimap will present the partnership at the New Zealand Aged Care Association in Wellington on 17th-18th November 2020:

https://nzaca.org.nz/events/conference-2020/

This release has been authorized for release by CEO Philip Daffas.

For more information:

Ian Hobson	Philip Daffas
Company Secretary, PainChek	CEO, PainChek
ian.hobson@painchek.com	philip.daffas@painchek.com
+61 8 9388 8290	0406 537 235

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

PainChek® is a smart phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek® records a short video of the person's face and analyses the images that indicate pain and records them.

Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.   To find out more, visit www.painchek.com

About Medi-map

The Medi-Map platform manages all aspects of medication in a facility-based environment. Charting, administration, supply and communication are integral components which allow a transparent, seamless cascade of care for each resident.

Medi-Map recognizes the need in the health and care sector for auditing and reporting and has developed audit tools and the ability for facility management to generate reports at individual facility level or at a wider corporate level.

Medi-Map has electronic prescription integration which enables prescriptions to be generated for supply from a pharmacy electronically once the prescriber has charted the medication or completed a scheduled medication review. To find out more, visit www.medimap.com.au.

ABN 21 146 035 127   **P:** +61 8 9388 8290
401, 35 Lime Street,   **E:** info@painchek.com   PainChek Limited (ASX: PCK) | PG 2
Sydney, NSW, 2000   **W:** painchek.com